Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 5:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 171 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Duke Cancer Institute Clear all
Recruiting Not applicable Interventional

Targeted Palliative Care Intervention for Patients With Metastatic Breast Cancer

NCT06795529
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Palliative Care Intervention, "TARGET-PC", Enhanced Usual Care
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
3
States / cities
Boston, Massachusetts • Durham, North Carolina • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Sep 30, 2026, 5:12 AM EDT
Completed Phase 1 Interventional

Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain Tumors

NCT00003484
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Neuroblastoma
Interventions
carmustine, irinotecan hydrochloride, surgical procedure, iodine I 131 monoclonal antibody 81C6
Drug · Procedure · Radiation
Lead sponsor
Darell D. Bigner, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2010
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 23, 2015 · Synced Sep 30, 2026, 5:12 AM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients Undergoing Surgery for Recurrent Glioblastoma Multiforme

NCT00890032
View directory record Official record
Conditions
Recurrent Central Nervous System Neoplasm
Interventions
BTSC mRNA-loaded DCs
Biological
Lead sponsor
John Sampson
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 17, 2016 · Synced Sep 30, 2026, 5:12 AM EDT
Completed Phase 2 Interventional

Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) With Bevacizumab and Irinotecan for Malignant Glioma

NCT00352521
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
bevacizumab, irinotecan, dynamic contrast-enhanced magnetic resonance imaging
Drug · Procedure
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 22, 2014 · Synced Sep 30, 2026, 5:12 AM EDT
Completed Phase 1Phase 2 Interventional

Temozolomide Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Malignant Glioma or Recurrent CNS or Other Solid Tumors

NCT00005952
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Head and Neck Cancer, Kidney Cancer, Neuroblastoma, Ovarian Cancer, Sarcoma, Testicular Germ Cell Tumor
Interventions
filgrastim, temozolomide, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Duke University
Other
Eligibility
Up to 18 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Sep 30, 2026, 5:12 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

ABC294640 (Opaganib) in Refractory / Relapsed Multiple Myeloma

NCT02757326
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Opaganib
Drug
Lead sponsor
RedHill Biopharma Limited
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 18, 2021 · Synced Sep 30, 2026, 5:12 AM EDT
Completed Not applicable Interventional

Study of Health Promotion in Patients With Early-Stage Breast or Prostate Cancer

NCT00037024
View directory record Official record
Conditions
Breast Cancer, Depression, Fatigue, Malnutrition, Prostate Cancer, Psychosocial Effects of Cancer and Its Treatment
Interventions
fatigue assessment and management, nutritional support, physical therapy, psychosocial assessment and care, quality-of-life assessment
Procedure
Lead sponsor
Duke University
Other
Eligibility
65 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Sep 30, 2026, 5:12 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Intervention Study of Communication in Oncologist-Patient Encounters

NCT00994578
View directory record Official record
Conditions
Advanced Cancer
Interventions
CHESS, COPE, CHESS/COPE
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
659 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
2
States / cities
Durham, North Carolina • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 12, 2014 · Synced Sep 30, 2026, 5:12 AM EDT
Terminated Phase 1Phase 2 Interventional

A Trial for Treatment of Cancer Patients With Multiple Brain Metastases Undergoing Whole-Brain Radiotherapy

NCT03608020
View directory record Official record
Conditions
Multiple Brain Metastases
Interventions
BMX-001, Whole Brain Radiation Therapy
Drug · Radiation
Lead sponsor
BioMimetix JV, LLC
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
4
States / cities
Lexington, Kentucky • Detroit, Michigan • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Sep 30, 2026, 5:12 AM EDT
Completed Phase 2 Interventional Results available

Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma

NCT00354913
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma
Interventions
hydroxyurea, imatinib mesylate
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 18, 2013 · Synced Sep 30, 2026, 5:12 AM EDT
Completed Not applicable Interventional

Diet and Exercise-Based Counseling Program Compared With a Standard Counseling Program in Patients With Early-Stage Prostate Cancer

NCT00044980
View directory record Official record
Conditions
Malnutrition, Prostate Cancer
Interventions
nutritional support, quality-of-life assessment
Procedure
Lead sponsor
Duke University
Other
Eligibility
18 Years to 120 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Sep 30, 2026, 5:12 AM EDT
Completed Phase 2 Interventional Results available

3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy

NCT01751451
View directory record Official record
Conditions
Prostate Cancer
Interventions
Abiraterone acetate, Abiraterone acetate plus degarelix, Degarelix
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
16
States / cities
Chicago, Illinois • Baltimore, Maryland • Detroit, Michigan + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2021 · Synced Sep 30, 2026, 5:12 AM EDT
Completed Not applicable Interventional

Improving Adherence to Recommended Surveillance in Breast Cancer Survivors

NCT02189278
View directory record Official record
Conditions
Breast Cancer
Interventions
Psychosocial Intervention
Behavioral
Lead sponsor
Duke University
Other
Eligibility
21 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 3, 2018 · Synced Sep 30, 2026, 5:12 AM EDT
Active, not recruiting Phase 2 Interventional

The Prevention of Progression to Pancreatic Cancer Trial (The 3P-C Trial)

NCT04207944
View directory record Official record
Conditions
IPMN, IPMN, Pancreatic
Interventions
Sulindac 400 MG, Placebo
Drug · Other
Lead sponsor
Duke University
Other
Eligibility
21 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
4
States / cities
Baltimore, Maryland • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 30, 2026, 5:12 AM EDT
Completed Not applicable Interventional

Four Conversations RCT

NCT02944344
View directory record Official record
Conditions
Breast Cancer
Interventions
Four Conversations
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
357 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 13, 2018 · Synced Sep 30, 2026, 5:12 AM EDT
Completed Phase 1 Interventional

Carmustine Wafers Plus Irinotecan in Treating Patients With Recurrent Supratentorial High Grade Gliomas

NCT00003463
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
carmustine, irinotecan hydrochloride, polifeprosan 20 with carmustine implant, surgical procedure
Drug · Procedure
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
2
States / cities
Los Angeles, California • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 18, 2013 · Synced Sep 30, 2026, 5:12 AM EDT
Completed Phase 1Phase 2 Interventional

MRI Sarcoma Non Invasive Thermometry

NCT00093509
View directory record Official record
Conditions
Sarcoma
Interventions
doxorubicin hydrochloride, ifosfamide and mesna, hyperthermia treatment with an MRI Compatible Radiofrequency Extremity Hyperthermia Applicator, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Mark Dewhirst
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2009
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 1, 2014 · Synced Sep 30, 2026, 5:12 AM EDT
Withdrawn Phase 1 Interventional

A Phase I Trial of Normothermic Isolated Limb Infusion (ILI) With Melphalan Plus Buthionine Sulfoximine (BSO) in Patients With Locally Advanced Malignant Melanoma

NCT00661336
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
buthionine sulfoximine, melphalan, microarray analysis, high performance liquid chromatography, laboratory biomarker analysis, pharmacological study, biopsy
Drug · Genetic · Other + 1 more
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
2
States / cities
Durham, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 13, 2015 · Synced Sep 30, 2026, 5:12 AM EDT
Completed No phase listed Observational

A Pharmacogenomics Study for Breast Cancer Patients Undergoing Adjuvant Chemotherapy With Doxorubicin (A)/Cyclophosphamide ©) and/or Weekly Paclitaxel

NCT00131963
View directory record Official record
Conditions
Breast Cancer
Interventions
cyclophosphamide, doxorubicin, paclitaxel
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2014
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 25, 2016 · Synced Sep 30, 2026, 5:12 AM EDT
Terminated Phase 2 Interventional Results available

Velcade + Cyclophosphamide in Newly Diagnosed Multiple Myeloma

NCT01729338
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Velcade, Cyclophosphamide, Revlimid
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Sep 30, 2026, 5:12 AM EDT
Completed Phase 1 Interventional Results available

PVSRIPO for Recurrent Glioblastoma (GBM)

NCT01491893
View directory record Official record
Conditions
GBM, Glioblastoma, Glioma, Malignant Glioma
Interventions
Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO)
Biological
Lead sponsor
Istari Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Sep 30, 2026, 5:12 AM EDT
Completed Phase 1Phase 2 Interventional

Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary Brain Tumors

NCT00003478
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
conventional surgery, iodine I 131 monoclonal antibody 81C6, radiation therapy
Procedure · Radiation
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2007
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 20, 2013 · Synced Sep 30, 2026, 5:12 AM EDT
Completed Phase 2 Interventional

Temozolomide in Treating Adults With Newly Diagnosed Primary Malignant Glioblastoma Multiforme

NCT00003464
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
temozolomide, radiation therapy
Drug · Radiation
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2003
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Sep 30, 2026, 5:12 AM EDT
Completed Phase 1Phase 2 Interventional

Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer

NCT00004211
View directory record Official record
Conditions
Prostate Cancer
Interventions
PSA RNA-pulsed dendritic cell vaccine
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 21, 2013 · Synced Sep 30, 2026, 5:12 AM EDT